GENFIT Reports Financial Developments for Q3 2025
GENFIT, a dedicated biopharmaceutical company focused on addressing the unmet medical needs of patients suffering from severe liver diseases, recently shared its financial outcomes for the third quarter of 2025. The company has diligently worked to bolster its efforts and advance its initiatives related to liver disease.
Cash and Financial Overview
As of September 30, 2025, GENFIT possesses cash and cash equivalents amounting to €119.0 million, a significant increase from €107.5 million at the end of the previous quarter, June 30, 2025. This rise is a positive sign of the company’s financial health, showing considerable support for ongoing projects and research.
GENFIT anticipates that its current cash position will comfortably support operational costs and development activities well into 2028. This projection is based on several critical assumptions, including anticipated future milestone payments from its licensing agreement with Ipsen, contingent upon Ipsen achieving specified sales thresholds.
Revenue Highlights
The total revenue for GENFIT during the first nine months of 2025 reached €39.2 million. This figure reflects a decrease compared to the same period in 2024, which recorded revenues of €59.7 million. The current revenue stream is primarily bolstered by the Licensing and Collaboration Agreement with Ipsen, demonstrating GENFIT’s strategic partnerships.
This revenue includes €12.6 million generated from royalties on global sales (excluding Greater China) of Ipsen's Iqirvo® (elafibranor), alongside €26.5 million contributed by milestone payments following the successful pricing and reimbursement approval of Iqirvo® in substantial European markets.
Pipeline Progress and Innovation
GENFIT’s commitment to discovering and developing novel therapeutic options is evident through its robust pipeline focused on Acute on-Chronic Liver Failure (ACLF) and other serious liver-related conditions. The following are key programs within the pipeline:
G1090N
Presently undergoing a Phase 1 First-in-Human study with healthy volunteers, G1090N is set to yield safety data towards the end of this year along with preliminary signs of efficacy derived from ex-vivo functional assays.
SRT-015
Development efforts on an enhanced formulation of SRT-015 aim to elevate exposure levels. Pending successful outcomes, the initiation of a first-in-human trial could occur in the latter half of 2026.
CLM-022
To substantiate therapeutic efficacy, experiments are ongoing using varied disease models pertinent to ACLF and related conditions. Aiming for further advancements, a first-in-human trial could kick-off in early 2027.
VS-02-HE
Seeking to minimize systemic absorption of ammonia, VS-02-HE is designed for oral use in the gut, with the goal of curbing glutamine levels in the brain. The culmination of nonclinical studies and formulation development is anticipated by year-end 2025, paving the way for potential human trials in late 2027.
Expansion into Other Critical Areas
Alongside its focus on liver diseases, GENFIT is also investing in treatments for cholangiocarcinoma (CCA) and urea cycle disorders. Data from the ongoing Phase 1b clinical trial for GNS561 are expected by the close of 2025, indicating a focus on life-threatening conditions beyond liver diseases. Additionally, pivotal data regarding the juvenile toxicology research of VS-01-HAC awaits release before year-end.
Strategic Partnerships and Market Presence
GENFIT continues to cultivate strategic partnerships to further its mission. According to Ipsen, Iqirvo® has exhibited robust growth in both U.S. and European markets, showcasing its potential as a key treatment option for Primary Biliary Cholangitis (PBC). GENFIT’s solid scientific foundation and dedicated expertise contribute to its innovation and growth within the industry.
Conclusion and Future Outlook
The journey ahead for GENFIT appears promising, bolstered by its strong financial footing and innovative pipeline. With a focus on developing impactful therapies for liver diseases and expanding into other significant areas, the company aims to make a profound difference in the lives of patients globally. Investors and stakeholders remain keenly interested in the unfolding developments as GENFIT continues to lead the charge in biopharmaceutical advancements.
Frequently Asked Questions
What is GENFIT's primary focus as a biopharmaceutical company?
GENFIT concentrates on improving the lives of patients with rare and life-threatening liver diseases through innovative research and drug development.
How much cash does GENFIT currently have available?
As of September 30, 2025, GENFIT reported cash and cash equivalents totaling €119.0 million.
What does GENFIT's revenue stream consist of?
The revenue primarily results from collaboration agreements, including substantial milestone payments and royalties from the sales of Iqirvo®.
What key programs are included in GENFIT's pipeline?
GENFIT’s pipeline includes G1090N, SRT-015, CLM-022, and VS-02-HE, each targeting critical liver conditions and aiming to enter first-in-human trials soon.
What is the significance of Iqirvo® for GENFIT?
Iqirvo® has witnessed solid market growth and serves as a vital treatment option for Primary Biliary Cholangitis (PBC), contributing significantly to GENFIT's revenue.
